RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according ...

Researchers have found in a nonrandomised pilot trial that selumetinib showed a reduction in cutaneous neurofibromatosis ...

After months of waiting, a young boy from Cuba battling a medical condition is getting a second chance at life after he and ...

Healx has dosed the first subject in the open-label Phase II INSPIRE-NF1 trial to assess the efficacy and safety of HLX-1502 in individuals with neurofibromatosis type 1 (NF1), a rare genetic disorder ...

Genetic changes alone don’t fully explain tumor growth in NF-1, pointing to other contributing factors. This insight may ...

Healx, an AI-enabled, clinical-stage biotech company dedicated to rare diseases, today announced the first patient has been dosed in INSPIRE-NF1, a Ph ...

Discover a study that used the Skindex-29 assessment to evaluate emotional wellbeing during selumetinib cycles.

Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform ...

New findings question assumptions of cancer formation in individuals with the cancer-predisposition syndrome, neurofibromatosis type 1, and offer hope for a personalized approach to early cancer ...

The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults and children. The drug, developed by SpringWorks Therapeutics, is the first ...

The night will honor Nick Gilbert, late son of Cavaliers Chairman Dan Gilbert. Fans will receive a special bobblehead as part ...